Pharmafile Logo
Pharmafocus logo
Advanced Search

MHRA

Showing 15 posts of 101 posts found.

brexit_flag_0

Ministers move to clarify drug regulation Post-Brexit

July 4, 2017
Manufacturing and Production, Medical Communications EMA, Jeremy Hunt, MHRA, NHS, NICE

Jeremy Hunt, Health Secretary, and Greg Clark, Business Secretary, have made a bold move to suggest that the UK will …

News
sanofi_new_paris_hq

Patients in UK to be given early access to Sanofi’s eczema treatment

March 14, 2017
Research and Development, Sales and Marketing Dupilumab, MHRA, Sanofi

Sanofi’s treatment for atopic dermatitis, otherwise known as eczema, has been given a positive scientific opinion through the MHRA’s Early …

News
brexit

Brexit could delay key drugs to UK patients, ex-MHRA chairman claims

February 10, 2017
Medical Communications, Sales and Marketing Cancer, MHRA, brexit

Former UK regulator and ex-chairman of the Medicines and Healthcare products Regulatory Agency (MHRA) Sir Alasdair Breckenridge has warned that …

News
social_media

Socially vigilant: Does pharmacovigilance need secondary data & social media?

February 6, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, MHRA, pharmacovigilance

As the world’s drug consumption continues to rise alongside advancements in the medical and pharmaceutical industries, so too do new …

Feature

MHRA accepts Roche’s Tecentriq into Early Access to Medicines scheme

January 25, 2017
Research and Development, Sales and Marketing MHRA, Roche, eams, tecentriq

Roche’s Tecentriq (atezolizumab) has scored another positive opinion, this time from the Medicines and Healthcare products Regulatory Agency (MHRA), which …

News
lab

MHRA suspends GMP certificate for Pfizer site in India

August 22, 2016
Manufacturing and Production, Sales and Marketing GMP, India, MHRA, Pfizer, ban, facility, import, suspend

The UK’s Medicines and Healthcare Products Agency (MHRA) has recommended that an Indian facility belonging to Pfizer’s Hospira unit be …

News
sanofi_pasteur_scientist

MHRA approves Sanofi Pasteur MSD’s four-strain influenza vaccine for UK use

July 25, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MHRA, Sanofi pasteur msd, UK, Vaccine, flu, influenza

Sanofi Pasteur MSD has announced the approval of the latest addition to its family of influenza vaccines in the UK: …

News
msd

MHRA approves new indication for MSD’s Ezetrol

February 26, 2016
Medical Communications, Research and Development, Sales and Marketing MHRA, MSD, NICE, ezetrol

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for MSD’s Ezetrol (ezetimibe), making it …

News
opdivo

UK lung cancer patients get early access to breakthrough BMS drug

February 5, 2016
Research and Development, Sales and Marketing Bristol-Myers Squibb, MHRA, NICE, eams, opdivo

UK lung cancer patients are to get access to Bristol Myers-Squibb’s Opdivo (nivolumab) through the Early Access to Medicines Scheme …

News
AstraZeneca plaque

AstraZeneca lung cancer drug clears UK market access hurdle

September 4, 2015
Sales and Marketing AZD9291, AstraZeneca, Early Access to Medicines Scheme, MHRA, NSCLC, eams, lung cancer, non-small cell lung cancer

Follow @Pharmafocus

News
Entresto

Novartis heart failure drug available via EAMS

September 3, 2015
Sales and Marketing Early Access to Medicines Scheme, Entresto, LCZ696, MHRA, Novartis, eams, heart failure, sacubitril/valsartan

Novartis has won the investigational heart failure treatment LCZ696 (sacubitril valsartan) will be available in the UK under the Early …

News

Opdivo launched in the UK for skin cancer

July 2, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer

Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …

News
Fake drugs image

£15.8 million UK haul of fake drugs

June 19, 2015
Manufacturing and Production, Sales and Marketing MHRA, counterfeit, drugs, fake, interpol

Counterfeit and unlicensed medicines and devices worth £15.8 million have been seized in the UK as part of a global …

News
Novartis image

Novartis heart drug steps closer to EAMS scheme

April 23, 2015
Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan

Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …

News

Novartis in major oncology drive

March 30, 2015
Research and Development, Sales and Marketing Cancer, FDA, MHRA, Novartis, aduro, ceritinib, eams, early access, zykadia

Novartis says it is ‘stepping up its efforts’ in cancer by launching major initiatives to discover new treatments to combat …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024